Efficacy and safety of rituximab in the treatment of eosinophilic granulomatosis with polyangiitis
Introduction Eosinophilic granulomatosis with polyangiitis (EGPA) is a subset of antineutrophil cytoplasmic antibodies (ANCA) associated vasculitis with distinct pathophysiological mechanisms, clinical features and treatment responses. Rituximab is a licensed therapy for granulomatosis with polyangi...
Saved in:
Main Authors: | David Jayne, Rachel B Jones, Vítor Teixeira, Aladdin J Mohammad, Rona Smith |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2019-06-01
|
Series: | RMD Open |
Online Access: | https://rmdopen.bmj.com/content/5/1/e000905.full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
THE 2015 INTERNATIONAL GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS
by: T. V. Beketova, et al.
Published: (2016-07-01) -
INTERLEUKIN-5 IS A NEW TARGET IN THE TREATMENT OF EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS
by: T. V. Beketova, et al.
Published: (2020-06-01) -
Eosinophilic granulomatosis with polyangiitis in comorbidpatient: is the immunological diagnostics always unambiguous
by: V. N. Marchenko, et al.
Published: (2020-04-01) -
Rituximab versus azathioprine in maintenance therapy of patients with granulomatosis with polyangiitis
by: Samira Alesaeidi, et al.
Published: (2025-06-01) -
A case of hereditary alpha tryptasemia and presumptive eosinophilic granulomatosis with polyangiitis
by: Sonia Iqbal, DO, et al.
Published: (2025-08-01)